Class summary at a glance.

Every drug in the Bile Acid Sequestrant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $168.2Mcombined across class
Total Rx claims: 1.5M557K unique beneficiaries
Generic mfrs (active): 26across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Colesevelam

Brand: Welchol · 398K Part D claims (CY24) · 132K beneficiaries · First FDA approval: 2018-05-17

9 generic mfrs 0 plans require PA

Low NADAC$0.276

→

Avg plan cost$1.33

Part D spend $74.0M 5× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Colestipol

Brand: Colestid · 816K Part D claims (CY24) · 289K beneficiaries · First FDA approval: 1977-04-04

6 generic mfrs 0 plans require PA

Low NADAC$0.272

→

Avg plan cost$0.624

Part D spend $67.0M 2× spread, current vs floor

Class share

40%

of class CY24 spend

View profile →

Cholestyramine

Brand: Prevalite · 296K Part D claims (CY24) · 136K beneficiaries · First FDA approval: 1996-02-01

11 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.145

→

Avg plan cost$0.575

Part D spend $27.2M 4× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Cholestyramine For Oral Suspension

— Part D claims (CY24) · First FDA approval: 1996-08-15

Brand-only (no generics)

Low NADAC$0.103

→

Avg plan cost$0.103

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cholestyramine Light

— Part D claims (CY24) · First FDA approval: 2021-12-15

Brand-only (no generics)

Low NADAC$0.103

→

Avg plan cost$0.380

Part D spend — 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cholestyramine Powder For Suspension

— Part D claims (CY24) · First FDA approval: 2021-10-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Choleystyramine Light

— Part D claims (CY24) · First FDA approval: 2021-10-20

Brand-only (no generics)

Low NADAC$0.796

→

Avg plan cost$0.796

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.